Background: Propofol lipid emulsion supports bacterial growth and various outbreaks of postoperative infection are attributed to extrinsic contamination. This study's objectives were to ascertain propofol administration practices among South African anaesthesiologists and to determine the influence of the 2014 South African Society of Anaesthesiologists (SASA) Guidelines for Infection Control in Anaesthesia. Methods: A total of 1 598 SASA members were invited to participate anonymously and 634 replies were received. Using a riskscoring system developed from 13 questionnaire items, 542 respondents who administer propofol infusions were stratified into Low-, Moderate-, High-and Very High-Risk groups. Results: The majority (65%) of the 542 participants who administer propofol infusions were classified as Moderate Risk, 29% as Low Risk and 6% as High and Very High Risk. Some 61% were aware of the SASA Guidelines, of whom 47.3% had studied them. The median risk-score of the Studied Guidelines group was significantly smaller (p < 0.001). They included a greater proportion who were categorised as low risk (58% vs. 45%) and a lower proportion who were moderate risk (38% vs. 51%). Proportions of high-risk individuals did not differ. Of the total 634 respondents, 247 used rubber-stoppered vials of whom 28% had studied the SASA Guidelines; 20% of the Studied Guidelines group often/always shared vial contents between patients versus 12% of those who had not studied them (p = 0.13). Conversely, 40% (studied group) versus 13.6% (not-studied group) often/always wiped the diaphragm and seldom/never shared vial contents between patients (p < 0.0001). In all, 25% of the total 634 respondents often/ always pre-prepared multiple propofol syringes; 5.0% diluted propofol and often/always pre-prepared syringes. Conclusion: Penetration of the SASA Guidelines was low. Differences in unsafe practices among anaesthesiologists who had read the guidelines were statistically significant but clinically inconsequential. This highlights a need for greater publicity, emphasising their practical importance.
Introduction
Anaesthetic workspaces in South Africa are prone to contamination, with subsequent risk of intraoperative transmission of pathogenic microorganisms. 1, 2 Propofol, being dissolved in a lipid emulsion of soya bean oil, glycerol and egg lecithin, is capable of supporting rapid bacterial and fungal growth [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] as well as promoting endotoxin production. 3 Furthermore, stability of hepatitis C virus in propofol has been demonstrated. 13 Reports of infections related to extrinsically contaminated propofol resulting from unsafe injection practices have appeared regularly since 1990. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Centres for disease control and anaesthetic associations, [24] [25] [26] [27] [28] [29] including the South African (SA) Association of Anaesthesiologists (SASA) 30 have published guidelines for prevention of anaesthetic-related infections. With regard to safe injection practices, all agree that syringes, needles, administration sets, ampoules and vials are for single use only and containers should be wiped with an alcohol swab before breaking the ampoule or penetrating the vial diaphragm. Furthermore, propofol should be discarded within 6 h and in the intensive care unit (ICU) within 12 h. The United States of America's Centers for Disease Control and Prevention (CDC) are conducting a 'One and Only Campaign' to raise awareness regarding safe injection practices amongst healthcare professionals and patients. 31 Despite these efforts, it appears that in several countries unsafe injection practices persist among anaesthetists. [32] [33] [34] [35] The SA Medicines Control Council issued a warning during 2000 concerning outbreaks of postoperative infections, involving 10 patients (including one fatality) that resulted from unsafe injection practices involving propofol. 36 Recently a survey among 91 anaesthetists working in 15 hospitals in KwaZulu-Natal revealed that unsafe injection practices were common. 37 The primary objectives of this study were: (1) To ascertain propofol injection practices among South African anaesthetists regarding the risk of infection transmission by means of a survey; (2) To determine the influence of the SASA Guidelines for Infection Control in Anaesthesia in South Africa 2014 (SASA Guidelines) on the propofol injection practices of SA anaesthetists. Secondary objectives were: (a) To determine whether propofol injection practices differed according to level of training (registered specialist vs. non-specialist), sector employed (private vs. public) and gender; (b) To estimate the prevalence of target-controlled infusions (TCI) among SA anaesthetists.
Methods
Approval for the study was obtained from the Health Research Ethics Committee (HREC) of the Faculty of Medicine & Health Sciences of Stellenbosch University, SA; (Institutional Review Board (IRB) Number: IRB0005239, Protocol Number S15/09/198). The survey was conducted in collaboration with the Anaesthesia Network for South Africa (ANSA), a SASA initiative that supports national collaborative research. Permission to conduct the survey amongst SASA members was obtained and ANSA was authorised by SASA to survey members on our behalf. SASA membership is approximately 1 700. We included registrars, associate members (general practitioner anaesthetists) and specialist anaesthesiologists in public and private practice who were accessible by email. Nurse members and members residing in other countries were excluded. Retired members who did not respond to the survey invitation, and whose contact details had not been updated, were excluded. We developed the questionnaire and collected the data using the Research Electronic Data Capture Consortium (REDCap) system, a secure application developed at Vanderbilt University. 38 The list of survey questions is presented in Appendix A.
An email invitation to participate in the survey was distributed to SASA members during November 2015. Potential participants were assured of anonymity, and informed about the purpose of the study and approval by SASA and HREC. By responding, the participant granted consent that his/her responses be used for the study. The invitation contained a link to the electronic questionnaire. Completed questionnaires were captured automatically and stored on a secure server. An incentive in the form of a prize could be won through a process of random selection. Non-responders received three reminders at 10-day intervals. Additional invitations to participate were distributed to non-responders during January 2016, followed by two reminders at 10-day intervals. We concluded the survey during February 2016. The sponsor's identity was revealed with the name of the prize-winner. Data were exported from the REDCap database to a comma-delimited file and imported to Microsoft Excel® (Microsoft Corp, Redmond, WA, USA).
Calculation of risk score
We constructed a risk-scoring system from the possible replies to 13 questions regarding handling of propofol ampules and syringes that we regarded as constituting infection risks (Appendix B). For example, in reply to the question 'Do you draw up leftover contents of a propofol glass ampule for the next patient?' , scores of 0, 1, 2 and 3 were allocated to the replies 'Never' , 'Rarely' , 'Often' and 'Always' respectively. The maximum total was 39. Scores were grouped into Low-, Moderate-, Highand Very High-Risk categories (Appendix B, Table 2 ). Risk scores were applied to the replies by the respondents, who indicated that their practices included administration of propofol by infusion. Rubber-stoppered vial usage was not included in the risk-score calculations and was analysed separately because only a minority of respondents were propofol vial users.
Statistical analysis
Statistical analysis was performed using MedCalc software. 39 Non-parametric methods were employed, the data being ordered and categorical. Risk scores were compared using the Mann-Whitney test when comparing two groups and KruskalWallis one-way analysis of variance for more than two groups, followed by multiple comparisons. Proportional data were compared using the chi-square test. An alpha value < 0.05 was accepted as statistically significant. Confidence intervals for the differences between two median values were calculated using Confidence Interval Analysis (CIA) software. 40 CIA employs the Hodges-Lehmann estimator for calculating a confidence interval between two population medians, described by Conover 41 and outlined in the book Statistics with Confidence by Altman et al.
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Results
We issued 1 598 invitations and received 634 satisfactorily completed replies (39.7%). Participants' mean age was 46.3 years (SD 11.6, range 26-78 years). 
Risk-scores analysis
Risk scores were applied to the replies by the 542 respondents who indicated that they administered propofol by infusion. The median infection-risk score was 11 (Range 0-27; IQR 8-14; 95% confidence interval (95% CI) 10-11). One participant was classified as Very High risk. Participants' scores and the frequency of scores in the various risk categories are portrayed in Figure 1 and Table 2 . The majority of the 542 participants (65%) were classified as Moderate-Risk. The next largest grouping was Low Risk (29%). High Risk and Very High Risk together comprised 6%. The extent to which the answers to each question contributed to the total of all the scores was obtained by calculating the total scores resulting from each of the 13 questions and expressing them as a percentage of the overall total ( Table 3 ). The first five of the ranked responses contributed 75% to the total.
Impact of the SASA Guidelines on infection-risk scores
Of the 542 scored respondents, 332 (61.3%) were aware of the SASA Guidelines, of whom 157 (47.3%) had studied them (29% of the 542). The impact of the SASA Guidelines is presented in Table  4 and Figure 2 . The median risk score of those who had studied the SASA Guidelines was significantly lower than those who had not (p < 0.001); however, the difference was small (95% CI 1-2 points). The studied-SASA-Guidelines group had a greater proportion of respondents who were categorised as Low Risk (58.4% vs. 45 .2%, p = 0.0026) and a lower proportion who were categorised as Moderate Risk (38.4% vs. 50.8%, p = 0.0045). There was no difference between the proportions of High-Risk individuals (3.2% vs 4.0%, p = 0.646).
Of the 157 who had studied the guidelines, 56 (35.7%) stated that they had subsequently changed their practices: 55 stated how their practices had changed (Appendix C). There was no significant difference in median risk scores between those who stated that they had changed their practices vs. those who had not (9, IQR 7-12, vs. 10, IQR 7-13, p = 0.12, Figure 3 ). None of those who stated that they had changed their practices achieved High-Risk scores, whereas eight of those who had not changed their practices did achieve High-Risk scores (median 18, range 18-27, one-tailed probability for Fisher's exact test p = 0.026). There was no difference between the two groups with regard to the proportions who achieved Low-Risk scores (p = 1.0).
Influence of training level, employment sector, gender and age on infection-risk scores (Table 4)
The median score of non-specialists was statistically significantly smaller than that of the specialist group (p = 0.038); however, the difference was trivial (95% CI 0-2 points). There were no significant differences between the median scores of practitioners working in the private vs. the public sector or males vs. females. There was no association between age and risk score (Spearman's rho = 0.003, p = 0.94).
Rubber-stoppered vial usage
Of the 634 respondents, 247 (40%) use rubber-stoppered vials. The majority (73.7%) worked in the private sector. Vial usage is depicted in Table 5 . Notably with regard to low-risk behaviour, 62.3% never share vial contents between patients; 21.1% stated that they always or often swabbed the diaphragm and never or seldom shared vial contents between patients. In terms of highrisk behaviour, 57.9% never swab the diaphragm; 11.7% stated that they never or seldom swabbed the diaphragm and always or often shared the vial contents.
Impact of the SASA Guidelines on rubber-stoppered vial usage
Seventy of the 247 respondents (28.3%) who use rubber-stoppered vials had studied the SASA Guidelines. The effect on those who had studied the SASA Guidelines is portrayed in Table 6 .
Prevalence of target-controlled propofol infusions
Most (95.5%) respondents who administer propofol by infusion stated that they administered propofol by target-controlled infusion (TCI) (518/542). The median percentage of patients to whom these respondents administered TCI was 20% (IQR 10-37%; 95% CI 17-21%; range 1-100%). Seventy-five respondents stated that they administered TCI for 75% or more of their cases. Figure 4 depicts a frequency histogram of the distribution of TCI infusions.
Discussion
Only 29% of participants who administer propofol infusions were classified as being of low risk, the majority (65%) scoring in the moderate-risk category. This is a disconcerting finding, as, in addition, a significant proportion (6%) scored as High Risk or Very High Risk. Prior to publication of the SASA Guidelines, a survey conducted among 91 anaesthetists in KwaZulu-Natal 37 found that 14% of the participants admitted to the reuse of syringes on different patients; 19% reused syringes on different patients after changing the needle or infusion set. Similar behaviour was demonstrated in our study, despite it being conducted after publication of the SASA Guidelines. In our study, 16% admitted to using the same propofol syringe for different patients and 21% to reusing 50 ml syringes for propofol infusions. Of these, 30% reuse extension tubing between patients. Thus it appears that little change in clinical practice has occurred since publication of the SASA Guidelines. It is concerning that 44% of the total of 634 participants pre-prepared multiple syringes (21% often and 3.6% always). It is of particular concern that 8.8% of participants diluted the propofol and pre-prepared syringes. These actions are particularly prone to transmission of infection, considering the contaminated environment of many SA operating rooms and that pre-prepared syringes may end up being used some hours after preparation. Vial usage was also disconcerting as 57.9% indicated that they never swab the diaphragm with an alcohol swab. Only 21% always or often swabbed the diaphragm and never or seldom shared the contents between patients. Furthermore almost 12% never or seldom swabbed the diaphragm and always or often shared the vial contents. Studying the SASA Guidelines did influence vial handling significantly, as 40% often/always wiped the diaphragm and seldom/never shared vial contents between patients versus 13.6% who had not studied the guidelines.
Failure to wipe the neck of the propofol ampoule made the greatest contribution to risk scores (Table 3) . Zacher et al. demonstrated that wiping the ampoule neck with alcohol prior to opening significantly reduced bacterial contamination of propofol ampoules. 43 This is of particular importance when preparing propofol infusions for TCI or total intravenous anaesthesia (TIVA), or for sedation during critical care, where the solution may be administered over several hours. The second major contributor related to the duration of propofol infusions in the intensive care unit (ICU) whereby participants were prepared The page number in the footer is not for bibliographic referencing www.tandfonline.com/ojaa 30 EDTA (ethylenediaminetetraacetic acid) can retard the 24-h growth of microorganisms 10-fold thereby reducing the microbial growth potential in propofol to that of a non-lipid medication. 45, 46 EDTA is an FDA-required antimicrobial propofol additive, which has reduced the incidence of propofol-related infections from an average of 39 to 9 infections per year. 17 Three propofol formulations are in common use in SA, of which only one (Diprivan ® , AstraZeneca) contains EDTA. The package insert stipulates that Diprivan is not an antimicrobially preserved agent; the EDTA retards bacterial growth, but does not prevent it, necessitating asepsis during propofol administration.
Some 62% of the total 634 respondents were aware of the SASA Guidelines but only 29% had studied them. Furthermore only 52% had read a propofol package insert, in which manufacturers warn of the propensity of propofol emulsions to promote bacterial growth and the necessity for aseptic procedures. Studying the SASA Guidelines had a statistically significant impact on participants' propofol handling practices. Besides achieving lower risk scores, those who had studied the guidelines had a greater proportion of low-risk scoring individuals and a smaller proportion with moderate-risk scores. However, both groups had similar proportions of high-risk scoring individuals. Results were analogous with regard to vial handling: Whereas those who had studied the SASA-Guidelines had a greater proportion of practitioners who demonstrated low-risk behaviour, both groups had similar proportions of individuals who admitted to high-risk habits. Thus moderate and high-risk behaviour persists despite studying the SASA Guidelines. We conclude that the influences exerted by the SASA Guidelines, although statistically significant, have been small and probably of no clinical importance. This study's disappointing result is not unique. A survey amongst 493 American Society of Anesthesologists (ASA) members reported that 34.4% never or rarely swabbed rubber-stoppered vials and 20% often or always reused syringes. 47 Those who had read the CDC guidelines for the prevention of occupational transmission of HIV/HBV were more likely to have good hygienic practices, but the association, although statistically significant, was weak (r 2 = 0.036) and furthermore they were not more likely to swab vials than those who had not read the guidelines. A similar survey among 272 New Zealand anaesthetists 34 reported that 32.4% had never read the national policy on infection control 24 ; 86.3% reused ampules between patients, 41.3% reused vials and 2.2% reused syringes. A five-hospital audit in south-east England 48 reported that only 49% of anaesthetists knew the Association of Anaesthetists guidelines. A survey among 1 015 ASA members 49 found that 58% reused syringes between patients and 66% reused needles to draw up drugs.
The large number of anaesthesiologists who practise TCI for a considerable number of cases indicates how readily the SA to allow more than 12 h to elapse before discarding propofol and giving sets. Of particular concern is that propofol intended for sedation is often diluted prior to administration, itself a risky action. Propofol package inserts clearly state that although propofol may be diluted with four parts of 5% glucose or 0.9% sodium chloride, it should be done aseptically. The United States Pharmacopeial Convention (USP) stipulates that compounding of medications should be conducted in an ISO-5 class environment (less than 3 520 particles of size 0.5 μm and larger per cubic metre) and that this is not achievable within the operating room environment. 44 An appraisal of 58 studies regarding propofol-related infections, including 20 outbreaks involving 144 patients and 10 deaths, 22 identified syringes, micro-droppers, vials, and IV stopcock dead space as the most frequently encountered reservoirs of extrinsically contaminated propofol, with previously used vials being the most common culprits. Of the infection outbreaks, hepatitis C contributed 18.1%, hepatitis B 4.2%, Candida albicans 21.5% and bacteria 47.2% (gram-positive 27.1%, gram-negative 20.1%). The incidence of contaminated syringes was approximately 6% in ICUs and operating rooms. The authors point out that these reports were all from industrialised countries (USA, UK, Europe, Australia and Taiwan) and they were of the opinion that propofol-related infections are under-reported. No reports from developing or low-income countries have been forthcoming where the problem is likely to be much greater due to economic restraints and lack of awareness leading to reuse of syringes, ampoules and vials. anaesthesiology profession has accepted the technology. However, because of the potential for long-duration infusions, our results emphasise the necessity for these practitioners to adopt safe injection practices.
Ketamine has been shown to exert antibacterial and antifungal activity 50 and, considering that it is also pharmaceutically compatible with propofol, 51 it may be argued that propofolketamine mixtures may reduce the risk of infection due to extrinsic contamination. Begec et al. 50 studied the growth rates of several micro-organisms and the minimal bactericidal concentrations of ketamine in mixtures with 1% propofol (without EDTA). Ketamine retained microbial activity for certain organisms, but at different concentrations. Growth of Staphylococcus aureus was not inhibited at the highest tested ketamine concentration. They warned that although propofolketamine mixtures may reduce the risk of infection caused by accidental contamination, ketamine's antibacterial activity varies and may be ineffective against certain pathogens. Furthermore we are not aware of studies documenting antiviral activity.
Apan et al. investigated the growth rates of several microorganisms in mixtures of remifentanil and 1% propofol. 52 They demonstrated concentration-dependent growth retardation, which they attributed to the presence of glycine, a buffer in remifentanil ampoules. However, no bactericidal activity was demonstrated, necessitating aseptic precautions. It should be noted that mixing propofol with other drugs technically constitutes a 'new drug' not approved by the SA Medicines Control Council. This has medicolegal implications, as the anaesthesiologist assumes responsibility for any side-effects/ complications.
The response rate to our survey was 39.7%, similar to two previous surveys (41% and 44%), 47, 49 but lower than the Ryan study (61%). 34 Contributing factors were technical problems experienced with the SASA website, necessitating repeated emails to ensure that all members received invitations. Furthermore invitations were sent under the auspices of ANSA, a newly established, little-known SASA entity, thus some members may have ignored the emails. Nevertheless we regard 634 completed responses as a suitably representative sample of the SASA membership.
Weaknesses of this study include an unvalidated risk-scoring system, but it would be unethical to validate the system by means of a randomised controlled trial. Additionally we did not enquire into other important infection-control practices, specifically hand-washing and glove usage.
Conclusion
Persistent inadequacies regarding the safe administration of propofol reveal that the SASA Guidelines were of low impact. With regard to those who had studied the guidelines, statistically significant differences in injection practices were small and probably not clinically important. In addition, only 60% of respondents were aware of the SASA Guidelines, of whom less than half had read them. More effort is required to persuade SA anaesthetists to comply with the safe injection practices outlined by the SASA Guidelines as well as the package inserts of the propofol suppliers. It is noteworthy that no reports of infection associated with propofol usage have occurred where safe injection practices have been followed. 53 Improved compliance is in the best interest of practitioners and patients alike. We, a combined study group from Stellenbosch University and the South African Society of Anaesthesiologists (SASA), invite you to take part in a survey concerning propofol injection practices by anaesthetists. It should not occupy more than five minutes of your time. The survey is completely anonymous and the data will be stored and encrypted in such a way that the identity of the participants cannot be retrieved. By participating you agree to your anonymous responses being used for research purposes. As participant, you will be eligible to win a sponsored prize (an iPad Mini). The Stellenbosch University Health Research Ethics Committee 1 has approved the study.
Please help us to gather as much accurate information as possible.
Sincerely
The propofol usage study group: JF Coetzee, H Kluyts, P Scheepers and A Breedt 
